The Upstate Global Health Institute is currently seeking individuals between 18-75 years of age and have history of Post-Treatment Lyme disease Syndrome (PTLDS).
Lyme disease is a public health crisis in the U.S. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop PTLDS. there are several thoughts as to why these persistent symptoms happen in some people one of them is that there is a persistent infection.
Ceftriaxone is an FDA-approved medication recognized as one of the most potent compounds to kill the agent of Lyme disease, but it isn’t used often for Lyme Disease outside of the most severe forms because it is given daily for 30 days. However, it has been shown to reduce fatigue and symptoms for 6 months after receiving the drug.
This study is looking to see if dosing of Ceftriaxone every 5 days over a period of 6 weeks will be safe, well tolerated and may be more effective than the placebo for subject with PTLDS.